[refurb]

As you can see from the lack of biosimilars in the US, manufacturing a biological is a hell of a lot more complex and expensive than doing it for a small molecule.

And in fact, since this is version 1.0, I’ll bet a better version comes out before any generic company launches.

[akvadrako]

If they come out with a new version, they must be expecting it to sell in a quantity that makes the investment worth it. So maybe the pricing worry is just a temporary concern.